Last updated: August 18, 2026
ADENOSCAN is the branded injectable form of adenosine used primarily for pharmacologic cardiac stress testing. Its commercial value has declined from a branded product opportunity to a mature hospital injectable market. The active ingredient is long off-patent, generic adenosine is widely available, and no standalone ADENOSCAN revenue is publicly reported. Current economics depend on hospital purchasing contracts, generic competition, supply reliability, and demand for myocardial perfusion imaging.
What is ADENOSCAN and how is it used?
ADENOSCAN is an intravenous adenosine product administered as a continuous infusion during radionuclide myocardial perfusion imaging in patients who cannot achieve adequate exercise stress. Adenosine produces coronary vasodilation and increases myocardial blood flow, allowing perfusion differences to be detected during imaging.[1]
Adenosine injection is also used more broadly for acute termination of paroxysmal supraventricular tachycardia, although ADENOSCAN's labeled indication is pharmacologic stress testing rather than rapid intravenous treatment of arrhythmia.[1]
| Attribute |
ADENOSCAN |
| Active ingredient |
Adenosine |
| Dosage form |
Sterile intravenous injection |
| Typical concentration |
3 mg/mL |
| Primary branded use |
Pharmacologic stress testing |
| Therapeutic class |
Coronary vasodilator; antiarrhythmic |
| Administration |
Continuous IV infusion for stress imaging |
| FDA approval history |
Original approval in the late 1980s |
| Regulatory category |
Small-molecule prescription drug |
| Current competitive status |
Mature, genericized injectable market |
| Biosimilar exposure |
None |
The product has a short pharmacologic half-life, generally less than 10 seconds, which limits systemic exposure but requires controlled intravenous administration.[1]
When did ADENOSCAN lose exclusivity?
ADENOSCAN lost meaningful market exclusivity after expiration of the underlying small-molecule and formulation protection. The product is now exposed to generic adenosine injection from multiple manufacturers.
The original approval dates to 1989, placing the product in a period when patent terms were materially shorter than the 20-year term measured from filing under the modern Hatch-Waxman system. Any original composition or use patents associated with adenosine injection would have expired decades ago.
ADENOSCAN exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| FDA approval of ADENOSCAN |
1989 |
Branded market entry |
| Early branded period |
1990s |
Limited competition and hospital adoption |
| Generic adenosine development |
1990s-2000s |
Progressive price pressure |
| Genericized hospital market |
2000s onward |
Brand substitution and contract purchasing |
| Current market |
2020s |
Commodity injectable economics |
ADENOSCAN does not have the profile of a recently approved medicine with remaining new chemical entity exclusivity, pediatric exclusivity, or a meaningful Orange Book patent barrier.
What patents protect ADENOSCAN?
No commercially significant unexpired patent estate is associated with the active ingredient adenosine or the historical ADENOSCAN product. Adenosine is a naturally occurring nucleoside and has been used clinically for decades.
Patent protection assessment
| Protection category |
Current relevance |
| Active-ingredient patent |
Expired |
| New chemical entity exclusivity |
Expired |
| Basic formulation patents |
Expired or commercially immaterial |
| Method-of-use patents |
No meaningful barrier identified for the labeled use |
| Device patents |
Not central to ADENOSCAN competition |
| Manufacturing patents |
Potentially relevant to cost and supply, but not a market-exclusion barrier |
| Pediatric exclusivity |
No current relevance |
| Orphan-drug exclusivity |
Not applicable |
The commercial moat is therefore operational rather than legal. Manufacturers may protect production know-how, quality systems, supplier relationships, fill-finish capacity, and regulatory files. Those protections can affect entry cost and supply continuity, but they do not prevent generic substitution in the same way an unexpired patent would.
What is the Orange Book status of ADENOSCAN?
ADENOSCAN is an FDA-approved prescription drug, but the product does not have a current patent-based exclusivity position comparable to newer branded medicines. FDA Orange Book analysis should distinguish between the historic branded NDA and current approved generic adenosine products.
Generic manufacturers generally enter through abbreviated new drug applications, relying on the reference product's established safety and efficacy. For a mature injectable such as adenosine, the principal regulatory issues are pharmaceutical equivalence, sterility, strength, concentration, container closure, labeling, and manufacturing controls.[2]
The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, is the key source for determining current reference-product and generic-equivalence listings.[2] The relevant commercial question is not whether ADENOSCAN has a meaningful remaining patent term. It is whether approved generic products carry an A-rating or otherwise qualify for substitution under applicable state pharmacy and hospital purchasing rules.
Which companies compete with ADENOSCAN?
Competition comes primarily from generic injectable-drug manufacturers rather than from branded cardiovascular companies. Suppliers have included large hospital-product manufacturers and specialty injectable companies such as:
- Hikma Pharmaceuticals
- Pfizer's Hospira business
- Fresenius Kabi
- Sagent Pharmaceuticals, now part of Nichi-Iko-related operations
- Teva Pharmaceutical Industries
- Other FDA-approved injectable manufacturers and contract manufacturers
The exact supplier set changes as companies enter, exit, transfer products, or experience manufacturing interruptions. Hospital formularies often purchase adenosine through group purchasing organizations and distributor contracts, which makes price, availability, and service reliability more important than brand recognition.
How does ADENOSCAN compare with generic adenosine?
| Factor |
ADENOSCAN |
Generic adenosine |
| Brand recognition |
Historically established |
Low individual brand recognition |
| Active ingredient |
Adenosine |
Adenosine |
| Clinical role |
Pharmacologic stress testing |
Stress testing and other approved uses, depending on labeling |
| Price position |
Usually premium if purchased as brand |
Lower contract price |
| Substitution risk |
High |
Primary market standard |
| Patent barrier |
None of material commercial effect |
None of material commercial effect |
| Purchasing driver |
Availability and contract terms |
Price, availability, quality, allocation history |
| Revenue growth potential |
Limited |
Volume and supply-contract dependent |
ADENOSCAN can retain niche demand where clinicians, hospital formularies, or ordering systems preserve the branded product. That demand does not create a durable pricing moat.
What is the financial trajectory for ADENOSCAN?
ADENOSCAN's financial trajectory is best characterized as long-term erosion followed by low-value stabilization. The product's revenue is not separately disclosed in the public financial statements of its historical or current commercial organizations. As a result, company-level annual reports do not provide a reliable standalone ADENOSCAN revenue series.
Financial trajectory
- Launch and adoption: ADENOSCAN benefited from adoption of pharmacologic stress imaging and the need for a predictable IV coronary vasodilator.
- Generic entry: Generic adenosine reduced price and weakened branded volume.
- Hospital commoditization: Purchasing moved toward formulary contracts, group purchasing organizations, and distributor availability.
- Mature phase: Revenue became dependent on procedure volume, supply continuity, and residual brand preference.
- Current outlook: Nominal revenue is likely stable to declining, while gross-margin pressure remains high.
The principal revenue pool is tied to stress imaging volumes. Demand can be affected by changes in cardiology practice, imaging reimbursement, use of exercise stress testing, echocardiography, PET perfusion imaging, coronary CT angiography, and alternative pharmacologic stress agents.
What factors drive the ADENOSCAN market?
Cardiac imaging volume
ADENOSCAN demand tracks the number of pharmacologic myocardial perfusion studies. Patients unable to exercise adequately remain the core population. Aging, obesity, peripheral vascular disease, orthopedic limitations, and cardiopulmonary disease support use, while shifts toward other diagnostic modalities can reduce demand.
Alternative pharmacologic stress agents
Regadenoson, marketed as LEXISCAN, is the principal commercial alternative in pharmacologic myocardial perfusion imaging. Regadenoson is administered as a single bolus, whereas adenosine requires an infusion. That difference can improve workflow and simplify administration, although acquisition cost, formulary policy, clinical contraindications, and local protocol determine product selection.[3]
Dipyridamole is another established alternative, although its use has declined in many settings relative to adenosine and regadenoson.
| Market factor |
Effect on ADENOSCAN |
| Higher pharmacologic stress-test volume |
Positive |
| Generic price competition |
Negative |
| Regadenoson adoption |
Negative |
| Hospital supply shortages |
Mixed, potentially positive for available suppliers |
| Group purchasing contracts |
Negative for brand pricing |
| Lower use of nuclear perfusion imaging |
Negative |
| Continued need for low-cost adenosine |
Positive for generic volume |
What formulations are protected by ADENOSCAN?
The principal product is an immediate-use sterile injectable solution. The formulation is commercially simple compared with long-acting injectables, liposomal products, depot formulations, or biologics.
Potential manufacturing barriers include:
- Sterile fill-finish capacity
- Control of endotoxin and particulate contamination
- Container-closure integrity
- Stability during storage and distribution
- Reliable adenosine raw-material supply
- Validated aseptic processing
- FDA inspection and current good manufacturing practice compliance
These factors can cause supply disruptions even when no patent prevents competition. Injectable products are particularly exposed to manufacturing interruptions because hospitals often maintain limited inventory and cannot easily substitute another concentration or presentation without protocol and pharmacy review.
What generic entry risks exist for ADENOSCAN?
Generic entry risk is high because the product has no meaningful remaining composition-of-matter exclusivity and is administered in a conventional injectable dosage form. The main risk is not a future patent challenge. It is continued price competition and substitution by already approved generic products.
Paragraph IV challenges
Paragraph IV litigation is not a central current risk for ADENOSCAN. Paragraph IV certifications challenge patents listed in the Orange Book for a reference drug. With the historic patent estate expired and no commercially meaningful listed protection expected to block generic supply, the market is more likely to experience ordinary generic competition than a new wave of patent litigation.[2]
Potential disputes may still arise around:
- Product-specific labeling
- Manufacturing controls
- Therapeutic-equivalence determinations
- Supply agreements
- FDA manufacturing inspections
- Distributor or hospital contracting
Those disputes would be operational or regulatory rather than classic branded patent litigation.
What is the biosimilar risk for ADENOSCAN?
There is no biosimilar risk. Adenosine is a chemically synthesized small molecule, not a biologic. Competitors enter through the ANDA pathway rather than the biosimilar pathway under the Public Health Service Act.[4]
The relevant competitive threats are generic ANDA products, alternative pharmacologic stress agents, and changes in diagnostic practice.
What patent litigation and settlement agreements affect ADENOSCAN?
No major current patent litigation or settlement agreement is central to ADENOSCAN's market position. The product's commercial history is defined by expiration of old protection and generic availability rather than by an active patent enforcement program.
A settlement involving a branded competitor or an alternative stress agent could affect the broader market, but it would not create meaningful exclusivity for ADENOSCAN absent a new, valid, and enforceable patent covering a specific product or use.
How strong is the ADENOSCAN patent estate?
The patent estate is weak from a commercial exclusion perspective.
| Patent-estate criterion |
Assessment |
| Composition-of-matter protection |
None remaining |
| Formulation protection |
No material barrier |
| Method-of-use protection |
No material barrier identified |
| Device protection |
Limited relevance |
| Manufacturing IP |
Possible process value, but not exclusionary |
| Litigation leverage |
Low |
| Generic vulnerability |
High |
| Licensing value |
Low unless tied to manufacturing or distribution |
ADENOSCAN's value is therefore primarily a supply-chain asset. A company controlling dependable sterile production can obtain hospital business even without patent protection. That value is vulnerable to contract rebidding, shortages, quality events, and lower-cost competitors.
How does ADENOSCAN compare with LEXISCAN?
LEXISCAN, the brand name for regadenoson, has a different commercial profile. Regadenoson was developed as a more convenient pharmacologic stress agent because it is given as a bolus rather than a prolonged adenosine infusion. Its branded market had greater historical pricing power and a more substantial commercial franchise.
| Factor |
ADENOSCAN |
LEXISCAN |
| Ingredient |
Adenosine |
Regadenoson |
| Administration |
IV infusion |
IV bolus |
| Market maturity |
Highly mature |
Mature, with greater historical brand value |
| Generic exposure |
Extensive |
Generic competition has emerged or developed over time |
| Administration burden |
Higher |
Lower |
| Main economic advantage |
Low acquisition cost |
Workflow convenience |
| Patent value |
Expired |
Historically more significant, but declining with generic entry |
ADENOSCAN remains relevant where cost is prioritized and infusion is operationally acceptable. LEXISCAN has been more attractive where labor efficiency, protocol simplicity, and rapid administration justify a higher acquisition price.
What is the FDA regulatory status of ADENOSCAN?
ADENOSCAN is an FDA-approved prescription injectable. The FDA-approved labeling identifies pharmacologic stress testing as its primary use and describes major contraindications, including certain conduction disorders, significant hypotension, bronchospastic disease, and hypersensitivity.[1]
FDA regulatory risk is concentrated in manufacturing compliance and product quality. Because the product is sterile and injectable, a manufacturing warning letter, recall, or facility shutdown can affect market supply quickly. This risk can create temporary pricing power for an approved supplier with available inventory, even in a patent-free market.
What licensing deals support ADENOSCAN?
No major recent licensing transaction is publicly associated with ADENOSCAN as a standalone commercial asset. Historical commercialization involved branded pharmaceutical companies and specialized hospital-product manufacturers, but the product's present value does not support the licensing economics associated with innovative drugs.
Potential transactions would more likely involve:
- Product rights bundled with other hospital injectables
- Contract manufacturing
- Regional distribution
- Portfolio acquisitions
- Supply agreements with hospitals or group purchasing organizations
Standalone licensing value is low because the active ingredient is generic, clinical differentiation is limited, and revenue is not publicly reported as a material branded franchise.
What generic launch scenarios exist for ADENOSCAN?
Base case
Generic adenosine remains the dominant supply source. ADENOSCAN retains limited residual use in selected hospitals, but pricing stays under pressure.
Upside case for suppliers
A manufacturing interruption removes one or more generic suppliers. Available manufacturers gain temporary volume and improved net pricing. The effect is usually temporary because other suppliers can respond when capacity returns.
Downside case for the brand
Hospitals eliminate ADENOSCAN from formularies and standardize on the lowest-cost therapeutically equivalent product. Branded volume falls toward a narrow residual base.
Strategic case
A supplier differentiates through ready-to-use packaging, reliable allocation, bundled hospital-injectable contracts, or improved pharmacy workflow. The advantage remains commercial rather than patent-based and can be lost at contract renewal.
What is the geographic coverage of ADENOSCAN?
The principal commercial opportunity is in the United States, where the product has an FDA approval and is subject to U.S. hospital procurement and generic-substitution practices. International markets may use adenosine injection under local brands or generic names rather than the ADENOSCAN trademark.
Geographic value depends on:
- Local marketing authorization
- Hospital procurement rules
- Reimbursement for myocardial perfusion imaging
- Availability of competing agents
- Local sterile-manufacturing capacity
- National tender systems
- Brand recognition among cardiology and nuclear-medicine providers
The United States remains the most relevant market for analyzing ADENOSCAN's historic brand and Orange Book status.
Key Takeaways
- ADENOSCAN is a mature adenosine injection product used mainly for pharmacologic cardiac stress testing.
- Its active ingredient and historical patent protection are long expired.
- Generic adenosine creates high substitution and pricing risk.
- No meaningful current Paragraph IV or patent-litigation barrier defines the market.
- The product has no biosimilar exposure because adenosine is a small molecule.
- Standalone ADENOSCAN revenue is not publicly disclosed.
- Financial performance is driven by procedure volume, hospital contracts, generic pricing, and supply reliability.
- Regadenoson, marketed as LEXISCAN, is the principal branded alternative because of its bolus administration.
- Manufacturing quality and sterile supply capacity are more important than patent ownership.
- ADENOSCAN has low standalone licensing value but may retain portfolio value in hospital-injectable transactions.
FAQs
Is ADENOSCAN still commercially relevant?
Yes, but primarily as a mature hospital injectable. Its commercial relevance comes from clinical familiarity, low-cost adenosine supply, and use in pharmacologic stress testing rather than from brand exclusivity.
Does ADENOSCAN have an unexpired U.S. patent?
No commercially meaningful unexpired patent barrier is associated with the historical adenosine injection product. Generic manufacturers compete through FDA-approved ANDAs.
Can generic adenosine replace ADENOSCAN?
Generic substitution is generally possible when the generic has appropriate FDA therapeutic-equivalence status and the product presentation meets clinical and institutional requirements. Hospital pharmacy policy and state law determine the practical substitution process.
Is adenosine injection used for supraventricular tachycardia?
Yes. Adenosine injection is widely used for acute termination or diagnosis of certain supraventricular tachyarrhythmias. The labeled use and presentation of an individual product should be checked because ADENOSCAN is principally labeled for pharmacologic stress testing.[1]
What is the main investment risk in the ADENOSCAN market?
The main risk is commodity pricing combined with declining brand volume. Supply interruptions can create short-term opportunities, but they do not establish durable pricing power or protect the product from generic competition.
References
-
U.S. Food and Drug Administration. (n.d.). Adenoscan (adenosine injection) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (n.d.). Lexiscan (regadenoson injection) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable biologic products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilar-biologic-products
